SCHEMBL23709692

SCHEMBL23709692

C=C(C)Sc1ccc(Cl)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB2 P05107 3/20 0.43
▸ ICAM1 P05362 3/20 0.43
▸ ITGAL P20701 3/20 0.43
▸ MAPT P10636 2/20 0.42
▸ GABRA1 P14867 4/20 0.41
▸ GABRG2 P18507 4/20 0.41
▸ GABRB3 P28472 4/20 0.41
▸ GABRB1 P18505 2/20 0.41
▸ GABRB2 P47870 2/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ TP53 P04637 1/20 0.39
▸ USP7 Q93009 3/20 0.38
▸ FSCN1 Q16658 1/20 0.38
▸ USP47 Q96K76 1/20 0.38
▸ FBP1 P09467 1/20 0.37
▸ PLA2G1B P04054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19312375 0.82 CYP3A4 (0.36) MAPTGABRA1GABRG2GABRB3GABRB1
SCHEMBL12661132 0.81 ALDH1A1 (0.48) ITGB2ICAM1ITGALMAPTMEN1
SCHEMBL8055409 0.77 ALDH1A1 (0.44) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL8033584 0.74 TSHR (0.38) MAPTMEN1KMT2ATSHRALDH1A1
SCHEMBL17001956 0.73 CRHR1 (0.37) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL32665834 0.72 ITGB2 (0.47) ITGB2ICAM1ITGALMAPTMEN1
SCHEMBL8779862 0.72 ITGB2 (0.50) ITGB2ICAM1ITGALMAPTMEN1
SCHEMBL10834427 0.72 ITGB2 (0.50) ITGB2ICAM1ITGALMAPTMEN1
SCHEMBL3165346 0.71 ITGB2 (0.72) ITGB2ICAM1ITGALMAPTMEN1
SCHEMBL224671 0.71 FBP1 (0.58) ITGB2ICAM1ITGALMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS ITGB2 2479/4885ICAM1 3963/4885ITGAL 4154/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS ITGB2 2802/4885ICAM1 4540/4885ITGAL 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback